GDRX Stock Recent News

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business out.

GDRX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced a new e-commerce experience for retail pharmacies that improves how consumers get their medications via the GoodRx platform. The company is launching the experience with Midwest-based retailer Hy-Vee. Now, when a person searches for their medication on GoodRx and selects Hy-Vee as their preferred pharmacy, the system will check for medication inventory, validate.

GoodRx is a great small-cap value stock to buy amid the recent downturn. I'm upgrading the stock to a buy. GoodRx showcases strong adjusted EBITDA despite slower growth, making it an attractive target for private equity deals as public equities become less appealing. The company's new CEO is driving a wholesale change in business strategy, chasing relationships directly with pharmaceutical manufacturers.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and man.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today released a new report, The Prescription Drug Gender Divide, detailing how women shoulder a significantly greater out-of-pocket cost burden than men. The data shows that in 2024, women spent $8.8 billion – or 30% – more than men on out-of-pocket prescription costs. Combined with the common responsibilities of managing a career, family planning, and caregiving, women are le.

GoodRx Holdings Inc. GDRX reported fourth-quarter revenue of $198.6 million, up slightly by 1% year over year, missing the management guidance of around $200 million and consensus of $199.75 million.

GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Aubrey Reynolds - Director, IR Wendy Barnes - CEO Chris McGinnis - CFO Conference Call Participants Lisa Gill - J.P. Morgan John Ransom - RJF Charles Rhyee - TD Cowen Michael Cherny - Leerink Partners Jenny Cao - Truist Scott Schoenhaus - KeyBanc Stan Berenshteyn - Wells Fargo Securities Steven Valiquette - Mizuho Securities Jay Jin - Morgan Stanley George Hill - Deutsche Bank Allen Lutz - Bank of America Operator Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx Fourth Quarter and Full Year 2024 Earnings Call.

While the top- and bottom-line numbers for GoodRx (GDRX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.08 per share a year ago.